A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Gary Middleton, H.L. Robbins, Peter Fletcher, Joshua Savage et autres
7 citationsnpj Precision Oncology
Manita Mehmi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
5Publications signalées
155Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Genomics and DiagnosticsLung Cancer Research StudiesPI3K/AKT/mTOR signaling in cancer
Publications récentes
Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)
Helen L. Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi et autres
2 citationsMolecular Cancer Therapeutics
MA06.06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J
Gary Middleton, P. Fletcher, Joshua Savage, Manita Mehmi et autres
0 citationsJournal of Thoracic Oncology
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton, Peter Fletcher, Sanjay Popat, Joshua Savage et autres
4 citationsNature
The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton, Peter Fletcher, Sanjay Popat, Joshua Savage et autres
142 citationsNature
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.